Randomized double blind clinical trial evaluating the Ellagic acid effects on insulin resistance, oxidative stress and sex hormones levels in women with polycystic ovarian syndrome

Table 1 The comparison of baseline characteristics of the participants

Variable		Mean ± SD Placebo(n = 28)	Mean ± SD Ellagic acid (n = 29)	P1
Age (years, Mean ± SD)	26.09 ± 1.53	25.74 ± 1.19	0.736	Age (years, Mean ± SD)
Height(cm)	160.71 ± 9.28	162.09 ± 8.33	0.77	Height(cm)
Weight (kg)	Before	69.71 ± 5.11	70.63 ± 4.15	0.68
	After	69.2 ± 5.07	70.06 ± 4.51	0.59
	P2	0.651	0.703
Body Mass Index (K g/m², Mean ± SD)	Before	26.99 ± 0.61	26.88 ± 0.59	0.519
	After	26.79 ± 0.62	26.66 ± 0.64	0.53
	P2	0.864	0.817
Physical activity (met-h/week)	Before	36.01 ± 3.5	37 ± 3.29	0.218
	After	36.11 ± 3.57	37.61 ± 3.41	0.109
	P2	0.401	0.347
Metformin dose		1599.03 ± 404.26	1609.11 ± 395.13	0.721

Data are expressed as means ± SD
P1: Comparison of the mean of baseline characteristics between the two groups of Ellagic acid and placebo (Independent samples t-test)
P2: Comparison of mean of baseline characteristics in each group at baseline and end of study (Paired samples t-test)

ISSN: 1757-2215